Multicenter Registry of Very Early and Late Clinical Outcomes to Everolimus-eluting Cobalt-Chromium Stent In Patients With ST Elevation Myocardial Infarction
Not Applicable
- Conditions
- STEMIST-elevation Acute Myocardial Infarction
- Interventions
- Device: CoCr-EES
- Registration Number
- NCT02792920
- Lead Sponsor
- Hyogo Brain and Heart Center
- Brief Summary
To compare early and late clinical outcomes with everolimus-eluting cobalt-chromium stent in patients with ST-elevation acute myocardial infarction, as well as identify the characteristics and efficacy of CoCr-EES.
Also, OCT sub-analysis will be conducted
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
- Patients with STEMI who are able to undergo CoCr-EES implantation.
- Patients with no history of PCI in the target vessel
- Patients who are 20 or older at the time of informed consent
- Patients who provided written informed consent by himself/herself
- Patients who are judged by their treating physician to be able to undergo PCI with CoCr-EES
- Patients for whom thrombus aspiration prior to CoCr-EES implantation can be recommended
- Patients who meet all the following vascular inclusion criteria i.Patients with target lesion in native coronary artery ii.Patients with visual maximum vessel diameter of the target stent site in target lesion
- Patients were obtained finally revascularization of TIMI 3 by visual observation in the target vessel
- Patients who are able to treat with CoCr-EES the diameter 2.5mm or more and 3.5mm or less and the length of 8mm or more and 28mm or less.
Exclusion Criteria
- Patients participating in the other ongoing registry or clinical study(except post-marketing surveillance of CoCr-EES), or receiving treatment which may impact on endpoints of this study.
- Patients presenting with cardiogenic shock
- Patients for whom 12-month and 36-month CAG and clinical follow up is considered difficult (patient's residence should also be taken into account)
- Patients with responsible lesion in left main trunk
- Patients with renal insufficiency or with chronic renal failure with serum creatinine level of 2.0mg/dL or higher at visit
- Patients on hemodialysis
- Patients with a known history of adverse drug reactions to aspirin, or clopidogrel or prasugrel (This may not apply if safety of ticlopidine is confirmed as an alternative drug.)
- Patients who are below the age of 20
- Women who were positive in pregnancy test or wish to become pregnant during study duration
- Patients who newly developed AMI attributable to the prior stented site
- Patients with a known history of allergy to drug, polymer, metal, and other materials used in CoCr-EES
- Patients diagnosed with hepatic insufficiency
- Patients with target lesion in saphenous vein graft
- Patients with active malignant tumor
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description CoCr-EES CoCr-EES -
- Primary Outcome Measures
Name Time Method Target vessel failure (TVF) 12 months Target vessel failure (TVF) at 12 months after CoCr-EES implantation. TVF consists of defined as cardiac death, target vessel-related recurrent myocardial infarction (MI) or Target Lesion Revascularization (TLR)
- Secondary Outcome Measures
Name Time Method Any Target Vessel Revascularization (TVR) 12 months and 36 months MI (QMI and Non-QMI) 12 months Any TLR 12 months and 36 months Death 12 months and 36 months MACE (Cardiac death, MI and TLR) 12 months and 36 months Definite or Probable stent thrombosis 12 months and 36 months
Trial Locations
- Locations (2)
Higashi Takarazuka Sato Hospital
🇯🇵Takarazuka, Hyogo, Japan
Hyogo Brain and Heart Center
🇯🇵Himeji, Hyogo,, Japan